rosiglitazone has been researched along with fibrinogen in 9 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 6 (66.67) | 29.6817 |
| 2010's | 3 (33.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Cowan, D; Kaski, JC; Sidhu, JS | 1 |
| Ciccarelli, L; Cicero, AF; Derosa, G; Ferrari, I; Gaddi, AV; Ghelfi, M; Peros, E; Piccinni, MN; Salvadeo, S | 1 |
| Hitoglou-Makedou, AD; Kazakos, KA; Lasaridis, AN; Mouslech, TF; Nilsson, PM; Sarafidis, PA; Stafylas, PC; Tourkantonis, AA; Yovos, JG | 1 |
| Farah, R; Lapin, O; Shurtz-Swirski, R | 1 |
| Araujo de Baptista, E; Baptista, T; Beaulieu, S; El Fakih, Y; Galeazzi, T; Rangel, N; Uzcátegui, E | 1 |
| Dzanković, F; Macić-Dzanković, A; Pojskić, B; Velija-Asimi, Z | 1 |
| Chao, TH; Chen, IC; Li, YH; Tsai, WC | 1 |
| Barrera, G; Cerbone, A; Ciamporcero, E; Dianzani, C; Dianzani, MU; Ferretti, C; Minelli, R; Pettazzoni, P; Pizzimenti, S; Roma, G; Toaldo, C; Ullio, C | 1 |
| Cander, S; Ersoy, C; Guclu, M; Oz Gul, O; Ozkaya, G; Sarandol, E; Unal, O | 1 |
7 trial(s) available for rosiglitazone and fibrinogen
| Article | Year |
|---|---|
The effects of rosiglitazone, a peroxisome proliferator-activated receptor-gamma agonist, on markers of endothelial cell activation, C-reactive protein, and fibrinogen levels in non-diabetic coronary artery disease patients.
Topics: Aged; Anti-Inflammatory Agents; Biomarkers; C-Reactive Protein; Coronary Artery Disease; Diabetes Mellitus; Endothelium, Vascular; Female; Fibrinogen; Humans; Insulin Resistance; Male; Middle Aged; Receptors, Cytoplasmic and Nuclear; Rosiglitazone; Thiazolidinediones; Transcription Factors; Vasodilator Agents | 2003 |
Antithrombotic effects of rosiglitazone-metformin versus glimepiride-metformin combination therapy in patients with type 2 diabetes mellitus and metabolic syndrome.
Topics: Blood Glucose; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Female; Fibrinogen; Fibrinolytic Agents; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Metabolic Syndrome; Metformin; Middle Aged; Plasminogen Activator Inhibitor 1; Rosiglitazone; Sulfonylurea Compounds; Thiazolidinediones; Tissue Plasminogen Activator | 2005 |
The effect of rosiglitazone on novel atherosclerotic risk factors in patients with type 2 diabetes mellitus and hypertension. An open-label observational study.
Topics: Aged; Arteriosclerosis; C-Reactive Protein; Diabetes Mellitus, Type 2; Female; Fibrinogen; Homocysteine; Humans; Hypertension; Hypoglycemic Agents; Lipoprotein(a); Male; Middle Aged; Risk Factors; Risk Reduction Behavior; Rosiglitazone; Thiazolidinediones | 2005 |
Rosiglitazone in the assistance of metabolic control during olanzapine administration in schizophrenia: a pilot double-blind, placebo-controlled, 12-week trial.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Body Mass Index; Body Weight; Double-Blind Method; Female; Fibrinogen; Hemoglobins; Humans; Hypoglycemic Agents; Insulin Resistance; Lipid Metabolism; Male; Metabolic Diseases; Middle Aged; Olanzapine; Pilot Projects; Rosiglitazone; Schizophrenia; Statistics as Topic; Thiazolidinediones | 2009 |
Evaluation of risk markers fluctuation during an initial therapy with rosiglitazon in patients suffering from metabolic syndrome.
Topics: Biomarkers; C-Reactive Protein; Diabetes Mellitus; Dose-Response Relationship, Drug; Female; Fibrinogen; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Longitudinal Studies; Male; Metabolic Syndrome; Risk Factors; Rosiglitazone; Thiazolidinediones; Treatment Outcome; Uric Acid | 2009 |
Rosiglitazone reduces plasma levels of inflammatory and hemostatic biomarkers and improves global endothelial function in habitual heavy smokers without diabetes mellitus or metabolic syndrome.
Topics: Adult; Biomarkers; C-Reactive Protein; Double-Blind Method; Endothelium; Endothelium-Dependent Relaxing Factors; Fibrinogen; Hemostasis; Humans; Hypoglycemic Agents; Male; Matrix Metalloproteinase 9; Middle Aged; Photoplethysmography; Rosiglitazone; Smoking; Thiazolidinediones | 2010 |
Effect of Rosiglitazone and Insulin Combination Therapy on Inflammation Parameters and Adipocytokine Levels in Patients with Type 1 DM.
Topics: Adipokines; Adiponectin; Adult; Aged; Blood Glucose; Diabetes Mellitus, Type 1; Drug Therapy, Combination; Enzyme-Linked Immunosorbent Assay; Female; Fibrinogen; Humans; Hyperglycemia; Hypoglycemic Agents; Inflammation; Insulin; Insulin Secretion; Leptin; Male; Middle Aged; Prognosis; Prospective Studies; Resistin; Rosiglitazone; Thiazolidinediones; Young Adult | 2015 |
2 other study(ies) available for rosiglitazone and fibrinogen
| Article | Year |
|---|---|
Intensification of oxidative stress and inflammation in type 2 diabetes despite antihyperglycemic treatment.
Topics: Adult; Aged; Apoptosis; C-Reactive Protein; Case-Control Studies; CD11b Antigen; Diabetes Mellitus, Type 2; Fibrinogen; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Inflammation; Insulin; Leukocytes, Mononuclear; Metformin; Middle Aged; Oxidative Stress; Rosiglitazone; Superoxides; Thiazolidinediones; Transferrin | 2008 |
Rosiglitazone and AS601245 decrease cell adhesion and migration through modulation of specific gene expression in human colon cancer cells.
Topics: Acetonitriles; Benzothiazoles; Cell Adhesion; Cell Line, Tumor; Cell Movement; Cell Proliferation; Colonic Neoplasms; Fibrinogen; Gene Expression; Humans; Oligonucleotide Array Sequence Analysis; Real-Time Polymerase Chain Reaction; Rosiglitazone; Thiazolidinediones | 2012 |